2,4-diethyl-1,2,3,4-tetrahydroisoquinoline | 1361105-37-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2,4-diethyl-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2,4-diethyl-3,4-dihydro-1H-isoquinoline
• CAS: 1361105-37-4
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: JIMSHMLCDQJGLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异喹啉 、 乙醇 在 palladium 10% on activated carbon 、 锌 作用下， 反应 40.0h， 以55%的产率得到2-ethyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  An efficient one pot transfer hydrogenation and N-alkylation of quinolines with alcohols mediated by Pd/C/Zn

  摘要：

  一种Pd/C/Zn混合物与醇类一起被证明是一种有效的转移加氢体系，能够转化吡啶衍生物。此外，这种金属混合物能够将醇类激活为氮烷基化试剂，在氢的自转移过程中使用。由吡啶衍生物制备的1,2,3,4-四氢喹啉和N-烷基化四氢喹啉在一步反应中获得了优异的产率。

  DOI：

  10.1039/c1ob05888f

文献信息

• Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
  申请人：Mjalli M. M. Adnan

  公开号：US20070213347A1

  公开（公告）日：2007-09-13

  This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

  本发明提供了某些化合物、它们的制备方法、包含这些化合物的药物组合物，并且它们在治疗人类或动物疾病方面的用途。本发明的化合物可用作高级糖基化终产物受体（RAGE）和其配体（如高级糖基化终产物（AGEs）、S100/calgranulin/EN-RAGE、β-淀粉样蛋白和amphoterin）之间相互作用的调节剂，并用于管理、治疗、控制或作为辅助治疗RAGE引起的人类疾病。这些疾病或疾病状态包括急性和慢性炎症、糖尿病晚期并发症的发展，如增加的血管通透性、肾病、动脉粥样硬化和视网膜病变，阿尔茨海默病的发展、勃起功能障碍以及肿瘤浸润和转移。
• Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith
  申请人：Mjalli Adnan M. M.

  公开号：US20090035302A1

  公开（公告）日：2009-02-05

  Disclosed are RAGE antagonist compounds that have the ability to reverse pre-existing amyloidosis. Treatment with the RAGE antagonist compounds described herein may be used to reduce plaque size and improve cognition for subjects in the later stages of Alzheimer's disease. Additionally, the RAGE antagonists described herein may be used to reduce the onset of plaque formation and thereby prevent loss of cognition and other symptoms associated with Alzheimer's Disease and other diseases of amyloid deposition.
• US7361678B2
  申请人：——

  公开号：US7361678B2

  公开（公告）日：2008-04-22
• US7737285B2
  申请人：——

  公开号：US7737285B2

  公开（公告）日：2010-06-15
• An efficient one pot transfer hydrogenation and N-alkylation of quinolines with alcohols mediated by Pd/C/Zn
  作者：Belén Abarca、Rosa Adam、Rafael Ballesteros

  DOI：10.1039/c1ob05888f

  日期：——

  A Pd/C/Zn mixture with alcohols has been revealed to be an efficient transfer hydrogenation system to quinolines. Furthermore, the metals mixture is able to activate alcohols as N-alkylating agents in a hydrogen autotransfer process. 1,2,3,4-Tetrahydroquinolines and N-alkylated tetrahydroquinolines from quinolines have been obtained with excellent yields in one step.

  一种Pd/C/Zn混合物与醇类一起被证明是一种有效的转移加氢体系，能够转化吡啶衍生物。此外，这种金属混合物能够将醇类激活为氮烷基化试剂，在氢的自转移过程中使用。由吡啶衍生物制备的1,2,3,4-四氢喹啉和N-烷基化四氢喹啉在一步反应中获得了优异的产率。